Featured articles

Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of ...READ MORE →

Dear Colleagues, Customers, and Collaborators: At our Newormics location in Austin, TX, we have been allowed to re-open. We have ...READ MORE →

Patent covers the vivoChip® invention that Newormics licensed for use in immobilization of C. elegans for high resolution imaging. AUSTIN, ...READ MORE →

More articles

Dear Customers, Colleagues, and Collaborators: At Newormics, we recognize that combating the spread of this new virus requires a global ...READ MORE →

Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and ...READ MORE →

The research of Newormics is featured in a special report in the July 2019 issue of DDNews in an article ...READ MORE →

Newormics is exhibiting at the 2019 UK C. elegans meeting at Imperial College London on September 16th. Come meet us ...READ MORE →

Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project ...READ MORE →

Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June - 24th June. ...READ MORE →

Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had ...READ MORE →

Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project "A ...READ MORE →